FDA grants supplemental claims for dairy and beef replacement heifers
Pennchlor and Rumensin approved in combination for more producers.
Over the past year, cattle producers had the opportunity to harness the therapeutic potential of Pennchlor (chlortetracycline Type A medicated article), coupled with the coccidiosis control and performance enhancements offered by Rumensin (monensin Type A medicated article) in their starter rations. But now, two new supplemental claims are available for the well-established combination of Pennchlor and Rumensin. These additional claims now extend this combination’s therapeutic advantages for dairy and beef replacement heifers.
At a time when input costs, including feed, are above historic levels, the ability to use these products in combination gives producers more options to improve the sustainability and efficiency of their business.
In addition to their well-established benefits, these additional claims offer a more comprehensive solution for the health and growth of replacement beef and dairy heifers. The combination of Pennchlor and Rumensin effectively treats bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella multocida, provided these pathogens are susceptible to chlortetracycline. Additionally, it promotes an increased rate of weight gain and aids in the prevention and control of coccidiosis due to Eimeria bovis and Eimeria zuernii.
“With these expanded claims, we are not only enhancing animal health but also giving producers more flexibility to adapt their treatment and feed programs and to optimize performance in their dairy and beef replacement heifers,” adds Dr. Padraig Lucey, Elanco dairy technical consultant.
“We are delighted to provide these new claims for dairy and beef replacement heifers. This reflects our unwavering commitment to deliver innovative solutions that empower livestock producers to produce healthier, more productive herds,” says Lisa Wallace, Pharmgate Animal Health marketing manager.